Mabwell Bioscience
Overview
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, a
Employees1325
Market Cap$12.0B
Revenue$745.3M
Listed OnShanghai Stock Exchange
Ticker688062
CEODr. Datao Liu Ph.D.
HeadquartersShanghai